Tyrosine Kinase Inhibitor Induced Proteinuria – A Review

Abstract

Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinasesʼ signal transduction pathways through an array of inhibitory mechanisms. Tyrosine kinases (TK) have an inevitable role in downstream signal transduction and the proliferation of tumour cells. Hence, tyrosine kinase inhibitors (TKIs) are frequently employed as anti-neoplastic agents in the treatment of colon, breast, kidney, and lung cancers. They can be used as single or combination therapy with other targeted therapies. It is understood that TKIs pose a risk of developing proteinuria in some patients as it can primarily result in dysfunction of the split diaphragm, constriction or blockage of capillary lumens mediated by the basement membrane, acute interstitial nephritis, or acute tubular necrosis. This paper reviews the mechanism of action of TKIs, the pathophysiological mechanism of TKI-induced proteinuria, and its management [Fig. 1]

Keywords

TKI - proteinuria - management - adverse effect

Publication History

Received: 24 April 2024

Accepted: 07 September 2024

Article published online:
15 October 2024

• References

• 1 Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187
• 2 Patterson KI, Brummer T, O’brien PM. et al. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-489
• 3 Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res 2020; 152: 104609
• 4 Jiao Q, Bi L, Ren Y. et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018; 17
• 5 Zwaans R, Thomson C. Ab initio calculations on 2-, 3-and 4- substituted quinolines in relation with their activity as protein tyrosine kinase inhibitors. Theochem 1996; 362: 51-68
• 6 Lamba V, Ghosh I. New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 2012; 18: 2936-2945
• 7 Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015; 36: 422-439
• 8 Wind S, Schnell D, Ebner T. et al. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 2017; 56: 235-250
• 9 Jha P, Jain N, Singh AK. Imatinib-induced Stevens-Johnsons syndrome. BMJ Case Rep 2013; 2013: bcr2012007926-bcr2012007926
• 10 Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 2011; 80: 1271-1277
• 11 Paschke L, Lincke T, Mühlberg KS. et al. Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials. Eur Thyroid J 2018; 7: 308-312
• 12 Prasoppokakorn T, Thanapirom K, Treeprasertsuk S. Nephrotic syndrome induced by lenvatinib treatment for hepatocellular carcinoma. Case Reports Hepatol 2022; 2022: 1-6
• 13 Lankhorst S, Jan Danser AH, van den Meiracker AH. Endothelin-1 and antiangiogenesis. Am J Physiol Regul Integr Comp Physiol 2016; 310: R230-R234
• 14 Teppo H-R, Soini Y, Karihtala P. Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy. Oxid Med Cell Longev 2017; 2017: 1-11
• 15 Fda.gov Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
• 16 Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist 2009; 14: 800-805
• 17 Managing common toxicities with new tyrosine kinase inhibitors. Cancer World Archive 2015; Available from https://archive.cancerworld.net/e-grandround/managing-common-toxicities-with-new-tyrosine-kinase-inhibitors/
• 18 Culhane J, Professor P. Chair Department of Pharmaceutical Sciences School of Pharmacy College of Notre Dame of Maryland Baltimore, Li ME, BCOP Advanced Practice Pharmacist–Oncology Thomas Jefferson University Hospital Philadelphia. Targeted therapy with tyrosine kinase inhibitors. Uspharmacist.com 2008; Available from https://www.uspharmacist.com/article/targeted-therapy-with-tyrosine-kinase-inhibitors
• 19 Tykerb (lapatinib) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2008\
• 20 Gu X, Zhang S, Zhang T. Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity. Cells 2021; 10: 869
• 21 Louwerens M, Appelhof BC, Verloop H. et al. Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol 2012; 167: 809-815
• 22 Wang Y, Fei D, Vanderlaan M. et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345
• 23 Miaskowski C, Dodd M, Lee K. et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage 2010; 40: 531-544
• 24 Fenton C, Patel A, Dinauer C. et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000; 10: 349-357
• 25 Louwerens M, Appelhof BC, Verloop H. et al. Fatigue and fatigue-related symptoms in patients treated for different causes of hypothyroidism. Eur J Endocrinol 2012; 167: 809-815
• 26 Izzedine H, Massard C, Spano JP. et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448
• 27 Eremina V, Sood M, Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716
• 28 Kido M, Du L, Sullivan CC. et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005; 46: 2116-2124
• 29 Robert C, Soria J-C, Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500
• 30 Baek SH, Kim H, Lee J. et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 2014; 29: 40
• 31 Mendel DB, Laird AD, Xin X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
• 32 Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl 2013; 11: 172-191
• 33 Miyake H, Harada K-I, Imai S. et al. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib. Int J Clin Oncol 2015; 20: 796-801
• 34 Ochiai S, Sato Y, Minakawa A. et al. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. BMC Nephrol 2019; 20
• 35 Kumar S. 2234 sorafenib-induced nephrotic syndrome in recurrent post-transplant hepatocellular carcinoma. Am J Gastroenterol 2019; 114: S1251-S1251
• 36 Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
• 37 Garovic VD, Wagner SJ, Petrovic LM. et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22: 1136-1143
• 38 Fu Z, Zhang S, Gu X. et al. LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues. Front Med (Lausanne) 2023; 10
• 39 Zheng Y, Zhang C, Miao C. et al. ABCG2 rs2231142 polymorphism is related to sunitinib-induced toxicity in metastatic renal cell carcinoma: a systematic review. AME Med J 2017; 2: 78-78
• 40 de Zeeuw D, Remuzzi G, Parving H-H. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
• 41 Hiremath S, Fergusson D, Doucette S. et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350-2360
• 42 Blanco S, Bonet J, López D. et al. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int 2005; 67: S10-S14
• 43 Hou FF, Xie D, Zhang X. et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898
• 44 Terada T, Noda S, Inui K-I. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 2015; 152: 125-134
• 45 Santos MLC, de Brito BB, da Silva FAF. et al. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol 2020; 11: 190-204
• 46 Schjoedt KJ, Astrup AS, Persson F. et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009; 52: 46-49
• 47 Burgess E, Muirhead N, Cotret D. et al. Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893-900
• 48 Rossing K, Schjoedt KJ, Jensen BR. et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198
• 49 Hollenberg NK, Parving H-H, Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926
• 50 Aranda P, Segura J, Ruilope LM. et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074-1079
• 51 Andersen S, Tarnow L, Rossing P. et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606
• 52 Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 2014; 7: 11-22